LifeMD, Inc. (NASDAQ:LFMD) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of LifeMD, Inc. (NASDAQ:LFMD) have received a consensus recommendation of “Moderate Buy” from the nine ratings firms that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $9.25.

Several equities analysts have weighed in on the company. Zacks Research raised LifeMD from a “strong sell” rating to a “hold” rating in a research report on Friday, December 19th. B. Riley dropped their price objective on shares of LifeMD from $12.00 to $10.00 and set a “buy” rating for the company in a report on Tuesday, November 18th. BTIG Research cut their target price on shares of LifeMD from $18.00 to $10.00 and set a “buy” rating on the stock in a research note on Tuesday, November 18th. Wall Street Zen cut shares of LifeMD from a “hold” rating to a “sell” rating in a research report on Saturday, November 22nd. Finally, Mizuho cut their price objective on LifeMD from $8.00 to $6.00 and set a “neutral” rating on the stock in a research report on Wednesday, November 19th.

Insiders Place Their Bets

In other LifeMD news, CMO Jessica Friedeman sold 15,000 shares of the company’s stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of $3.61, for a total transaction of $54,150.00. Following the sale, the chief marketing officer owned 205,000 shares in the company, valued at $740,050. This represents a 6.82% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 18.40% of the stock is currently owned by company insiders.

Institutional Trading of LifeMD

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Arrowstreet Capital Limited Partnership lifted its holdings in shares of LifeMD by 1,767.8% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 434,937 shares of the company’s stock valued at $5,924,000 after purchasing an additional 411,651 shares during the last quarter. JPMorgan Chase & Co. increased its position in LifeMD by 581.2% during the second quarter. JPMorgan Chase & Co. now owns 412,571 shares of the company’s stock worth $5,619,000 after buying an additional 352,004 shares during the period. Jump Financial LLC lifted its stake in LifeMD by 205.0% in the second quarter. Jump Financial LLC now owns 515,052 shares of the company’s stock valued at $7,015,000 after buying an additional 346,171 shares during the last quarter. Invesco Ltd. lifted its stake in LifeMD by 1,904.0% in the second quarter. Invesco Ltd. now owns 327,080 shares of the company’s stock valued at $4,455,000 after buying an additional 310,759 shares during the last quarter. Finally, Acadian Asset Management LLC purchased a new position in shares of LifeMD during the second quarter worth approximately $3,828,000. 35.52% of the stock is currently owned by institutional investors and hedge funds.

LifeMD Stock Performance

LifeMD stock opened at $3.58 on Monday. The company has a market capitalization of $172.34 million, a PE ratio of -21.06 and a beta of 1.45. LifeMD has a fifty-two week low of $3.18 and a fifty-two week high of $15.84. The firm has a 50 day moving average price of $3.70 and a 200 day moving average price of $5.94.

LifeMD (NASDAQ:LFMD) last released its quarterly earnings results on Monday, November 17th. The company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.04). The business had revenue of $60.17 million during the quarter, compared to the consensus estimate of $62.07 million. During the same quarter last year, the business earned $0.09 EPS. As a group, equities research analysts forecast that LifeMD will post -0.56 earnings per share for the current year.

About LifeMD

LifeMD (NASDAQ: LFMD) is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company’s core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.

LifeMD’s service portfolio spans several specialty areas, including men’s health, hormonal therapy, weight management and primary care.